Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

The novel Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated high response rates in B-cell lymphomas; however, a growing number of ibrutinib-treated patients relapse with resistance and fulminant progression. Using chemical proteomics and an organotypic cell-based drug screening assa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Autores principales: Zhao, Xiaohong, Lwin, Tint, Silva, Ariosto, Shah, Bijal, Tao, Jiangchuan, Fang, Bin, Zhang, Liang, Fu, Kai, Bi, Chengfeng, Li, Jiannong, Jiang, Huijuan, Meads, Mark B., Jacobson, Timothy, Silva, Maria, Distler, Allison, Darville, Lancia, Zhang, Ling, Han, Ying, Rebatchouk, Dmitri, Di Liberto, Maurizio, Moscinski, Lynn C., Koomen, John M., Dalton, William S., Shain, Kenneth H., Wang, Michael, Sotomayor, Eduardo, Tao, Jianguo
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5399304/
https://ncbi.nlm.nih.gov/pubmed/28416797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms14920
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares